–Presentation to be given at the 2026 Society for Neuro-Oncology Annual Meeting will highlight two high grade glioma patients with sustained immunosurveillance in brain cancer offering a promising treatment path — Philadelphia, PA – November 2, 2026 – Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of neoantigen targeted personalized DNA … Read more The post Geneos Therapeutics Announces Scientific Meeting Presentation of Sustained Immunosurveillance and Progression-free Survival in Two Brain Cancer Patients Treated with Neoantigen Targeted Personaliz